CU24461B1 - Compuestos útiles para tratar envejecimiento prematuro y en particular progeria - Google Patents

Compuestos útiles para tratar envejecimiento prematuro y en particular progeria

Info

Publication number
CU24461B1
CU24461B1 CU2011000228A CU20110228A CU24461B1 CU 24461 B1 CU24461 B1 CU 24461B1 CU 2011000228 A CU2011000228 A CU 2011000228A CU 20110228 A CU20110228 A CU 20110228A CU 24461 B1 CU24461 B1 CU 24461B1
Authority
CU
Cuba
Prior art keywords
premature aging
useful compounds
progeria
treat
treat premature
Prior art date
Application number
CU2011000228A
Other languages
English (en)
Other versions
CU20110228A7 (es
Inventor
Florence Mahuteau
Romain Najman
Julien Santo
Didier Scherrer
Jamal Tazi
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Univ Montpellier filed Critical Abivax
Publication of CU20110228A7 publication Critical patent/CU20110228A7/es
Publication of CU24461B1 publication Critical patent/CU24461B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

<p>La presente invención se refiere a compuestos de fórmula Ia</p> <p>ESPACIO PARA FÓRMULA</p> <p>y sales farmacéuticamente aceptables de los mismos, que se seleccionan de tartrato, citrato, trifluoroacetato, hidrobromoda, hidroclórido, tartrato, ascorbato, triflato, maleato, mesilato, formato, acetato y fumarato.</p> <p>Los compuestos de la invención son útiles para tratar enfermedades relacionadas con envejecimiento prematuro, en particular para inhibir, prevenir y/o tratar progeria.</p>
CU2011000228A 2009-06-12 2010-06-14 Compuestos útiles para tratar envejecimiento prematuro y en particular progeria CU24461B1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18655209P 2009-06-12 2009-06-12
US18654409P 2009-06-12 2009-06-12
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
PCT/IB2010/052652 WO2010143170A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating premature aging and in particular progeria

Publications (2)

Publication Number Publication Date
CU20110228A7 CU20110228A7 (es) 2012-04-15
CU24461B1 true CU24461B1 (es) 2020-01-03

Family

ID=43309298

Family Applications (4)

Application Number Title Priority Date Filing Date
CU2011000228A CU24461B1 (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar envejecimiento prematuro y en particular progeria
CUP2011000229A CU24124B1 (es) 2009-06-12 2010-06-14 N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer.
CUP2015000024A CU24245B1 (es) 2009-06-12 2010-06-14 QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS
CU2011000230A CU24093B1 (es) 2009-06-12 2010-06-14 Derivados de isoquinolina vinculados al proceso de empalme celular

Family Applications After (3)

Application Number Title Priority Date Filing Date
CUP2011000229A CU24124B1 (es) 2009-06-12 2010-06-14 N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer.
CUP2015000024A CU24245B1 (es) 2009-06-12 2010-06-14 QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS
CU2011000230A CU24093B1 (es) 2009-06-12 2010-06-14 Derivados de isoquinolina vinculados al proceso de empalme celular

Country Status (23)

Country Link
US (7) US20120277230A1 (es)
EP (6) EP3521283B1 (es)
JP (8) JP5905385B2 (es)
KR (14) KR101982461B1 (es)
CN (13) CN102574835B (es)
AU (3) AU2010258295B2 (es)
BR (5) BR122019013687B1 (es)
CA (5) CA3070823C (es)
CU (4) CU24461B1 (es)
DK (4) DK2440545T3 (es)
ES (4) ES2985082T3 (es)
FI (3) FI3517534T3 (es)
HR (3) HRP20230248T1 (es)
HU (2) HUE045548T2 (es)
LT (1) LT2440547T (es)
MX (10) MX359575B (es)
PL (4) PL2440547T3 (es)
PT (4) PT2440547T (es)
RU (1) RU2567752C2 (es)
SI (1) SI2440547T1 (es)
TR (1) TR201910781T4 (es)
WO (3) WO2010143168A2 (es)
ZA (2) ZA201109031B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2440547T1 (sl) * 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
PH12012500382A1 (en) 2009-09-03 2012-10-22 Bioenergenix Heterocyclic compounds for the inhibition of pask
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
CA2823753C (en) 2011-01-05 2019-03-12 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
BR112013022147A2 (pt) 2011-03-02 2017-04-25 Bioenergenix composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2014065209A1 (ja) * 2012-10-23 2014-05-01 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CA2916623C (en) * 2013-07-05 2021-09-14 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
JPWO2015005491A1 (ja) 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
CA2973942C (en) 2015-01-30 2023-07-11 Centre National De La Recherche Scientifique (Cnrs) Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11129824B2 (en) 2015-12-17 2021-09-28 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
WO2017103931A1 (en) * 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
CA3010690A1 (en) * 2016-02-03 2017-08-10 Janssen Pharmaceutica Nv Tau pet imaging ligands
PT3429998T (pt) 2016-03-18 2021-11-04 Prosynergia S A R L Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
JP2020525459A (ja) * 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
US10889566B2 (en) 2017-08-29 2021-01-12 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
US12528810B2 (en) * 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594205A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
AU2020276793A1 (en) 2019-05-15 2022-01-20 Alonbio Ltd. Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
CA3164700A1 (en) 2020-01-31 2021-08-05 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
US20230142547A1 (en) 2020-03-20 2023-05-11 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it) 2020-07-02 2025-09-12 Incyte Corp Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
US20240327388A1 (en) 2021-05-27 2024-10-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
TW202333698A (zh) * 2022-01-24 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 喹啉胺類化合物、其製備方法及其在醫藥上的應用
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物
EP4624469A4 (en) 2022-11-25 2026-04-15 Jiangsu Hengrui Pharmaceuticals Co Ltd CRYSTALLINE FORM OF QUINOLEIN AMINE COMPOUND AND ITS PREPARATION PROCESS
KR20260042485A (ko) 2023-08-01 2026-03-31 아비박스 궤양성 대장염의 치료를 위한 오베파지모드
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating microRNA activity A-124

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (es) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO2000059875A2 (en) * 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1539697A1 (en) * 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (en) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
CN1882345A (zh) * 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
CA2546353A1 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
CN101213260A (zh) 2005-06-29 2008-07-02 株式会社Adeka 树脂添加剂组合物和其树脂组合物
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
MX2009007661A (es) * 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) * 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
US8222634B2 (en) 2007-05-17 2012-07-17 Lg Chem, Ltd. Anthracene derivatives and organic electronic device using the same
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
AU2008286760A1 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
WO2010076339A1 (en) * 2009-01-05 2010-07-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
US20120172617A1 (en) * 2009-01-06 2012-07-05 Werner Bonrath resveratrol intermediates dal
ES2630226T3 (es) * 2009-01-06 2017-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Un agente agotador de células B para el tratamiento de la aterosclerosis
SI2440547T1 (sl) * 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
HRP20191460T1 (hr) 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP2016504268A (ja) 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Also Published As

Publication number Publication date
KR101863021B1 (ko) 2018-05-30
CN104844570B (zh) 2018-11-02
EP2440545A2 (en) 2012-04-18
EP2440546B1 (en) 2022-12-28
JP2015187152A (ja) 2015-10-29
BR122019013687B1 (pt) 2020-04-14
EP2440546A2 (en) 2012-04-18
BRPI1012892B1 (pt) 2020-10-27
ES2938532T3 (es) 2023-04-12
DK2440546T3 (da) 2023-03-27
JP6158251B2 (ja) 2017-07-05
HK1200363A1 (en) 2015-08-07
CN106928194A (zh) 2017-07-07
WO2010143168A3 (en) 2011-06-09
FI3517534T3 (fi) 2024-05-16
CN104844570A (zh) 2015-08-19
LT2440547T (lt) 2023-03-10
KR20190018571A (ko) 2019-02-22
EP3517534B1 (en) 2024-02-28
CN103948594A (zh) 2014-07-30
KR101789275B1 (ko) 2017-11-20
PT2440546T (pt) 2023-03-27
CN109776496A (zh) 2019-05-21
WO2010143170A2 (en) 2010-12-16
KR20120049860A (ko) 2012-05-17
CU20110230A7 (es) 2012-04-15
US9637475B2 (en) 2017-05-02
FI2440546T3 (fi) 2023-03-30
HK1212990A1 (zh) 2016-06-24
CN106905232B (zh) 2019-09-27
CN104945378A (zh) 2015-09-30
JP2012529493A (ja) 2012-11-22
ES2985082T3 (es) 2024-11-04
DK2440545T3 (da) 2019-07-22
KR20180100735A (ko) 2018-09-11
CA2764026A1 (en) 2010-12-16
PL2440545T3 (pl) 2019-11-29
CN104945378B (zh) 2018-11-20
MX367601B (es) 2019-08-28
KR102016890B1 (ko) 2019-08-30
HRP20230248T1 (hr) 2023-04-14
KR101769616B1 (ko) 2017-08-18
DK3517534T3 (da) 2024-05-27
KR20190018567A (ko) 2019-02-22
CA3070823A1 (en) 2010-12-16
PL2440546T3 (pl) 2023-07-10
US20150307478A1 (en) 2015-10-29
PL2440547T3 (pl) 2023-09-11
EP3517534A1 (en) 2019-07-31
CA2764026C (en) 2019-10-29
MX338823B (es) 2016-05-03
KR102016892B1 (ko) 2019-08-30
US9108919B2 (en) 2015-08-18
US20150299129A1 (en) 2015-10-22
CA2764024A1 (en) 2010-12-16
HK1173447A1 (zh) 2013-05-16
MX2011013120A (es) 2012-07-23
CN104945379A (zh) 2015-09-30
MX359575B (es) 2018-10-03
PL3517534T3 (pl) 2024-06-24
CN106905232A (zh) 2017-06-30
CU20110229A7 (es) 2012-06-21
BRPI1010772A2 (pt) 2016-11-01
CA3070823C (en) 2021-09-21
PT2440547T (pt) 2023-02-17
CN106928205B (zh) 2019-09-24
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
ES2940885T3 (es) 2023-05-12
MX364279B (es) 2019-04-22
FI2440547T3 (fi) 2023-03-14
ES2736198T3 (es) 2019-12-26
BRPI1012892B8 (pt) 2021-05-25
JP7042245B2 (ja) 2022-03-25
KR20190018568A (ko) 2019-02-22
AU2010258294A1 (en) 2012-01-19
KR20170124646A (ko) 2017-11-10
ZA201109032B (en) 2013-02-27
US20120277230A1 (en) 2012-11-01
RU2011149572A (ru) 2013-07-20
KR102016893B1 (ko) 2019-08-30
EP3521283A1 (en) 2019-08-07
BRPI1010768B1 (pt) 2019-10-22
KR101982463B1 (ko) 2019-05-24
SI2440547T1 (sl) 2023-05-31
CN102625804B (zh) 2015-04-08
CN106928194B (zh) 2019-11-12
KR20190018570A (ko) 2019-02-22
PT3517534T (pt) 2024-05-17
AU2010258214B2 (en) 2015-08-20
CU20150024A7 (es) 2015-09-29
EP4198022A1 (en) 2023-06-21
CN102625804A (zh) 2012-08-01
JP2015187150A (ja) 2015-10-29
CU24245B1 (es) 2017-02-02
HUE045548T2 (hu) 2019-12-30
US20140288120A1 (en) 2014-09-25
HK1213246A1 (zh) 2016-06-30
KR102016891B1 (ko) 2019-08-30
CA2764027C (en) 2020-11-03
US20140080831A1 (en) 2014-03-20
HK1173726A1 (zh) 2013-05-24
JP2015187151A (ja) 2015-10-29
CA2965791A1 (en) 2010-12-16
WO2010143168A2 (en) 2010-12-16
JP6041671B2 (ja) 2016-12-14
KR101973348B1 (ko) 2019-04-26
BRPI1010772B1 (pt) 2020-10-27
CN109776496B (zh) 2021-09-28
US10017498B2 (en) 2018-07-10
KR102016889B1 (ko) 2019-08-30
HK1212702A1 (zh) 2016-06-17
MX373120B (es) 2020-04-30
EP2440547B1 (en) 2022-11-30
JP2012529494A (ja) 2012-11-22
HUE061262T2 (hu) 2023-05-28
KR20170092720A (ko) 2017-08-11
AU2010258295A1 (en) 2012-01-19
ZA201109031B (en) 2013-02-27
WO2010143169A3 (en) 2011-11-10
RU2567752C2 (ru) 2015-11-10
MX2011013119A (es) 2012-07-04
KR20180100737A (ko) 2018-09-11
CN102574835A (zh) 2012-07-11
AU2010258214A1 (en) 2012-01-19
HK1213247A1 (zh) 2016-06-30
MX353776B (es) 2018-01-29
CN102596935B (zh) 2015-02-18
KR101897221B1 (ko) 2018-09-10
JP2015155453A (ja) 2015-08-27
CU24093B1 (es) 2015-04-29
KR20190018569A (ko) 2019-02-22
WO2010143169A2 (en) 2010-12-16
CN113004249A (zh) 2021-06-22
EP2440547A2 (en) 2012-04-18
CN104945379B (zh) 2018-11-30
CN104844510B (zh) 2019-04-23
HK1173153A1 (en) 2013-05-10
CA2965791C (en) 2020-06-09
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
KR101982461B1 (ko) 2019-05-24
HRP20240582T1 (hr) 2024-07-19
JP2012529495A (ja) 2012-11-22
RU2011149571A (ru) 2013-07-20
AU2010258295B2 (en) 2015-09-03
BRPI1010768A2 (pt) 2016-11-01
US9145367B2 (en) 2015-09-29
CN106928205A (zh) 2017-07-07
MX2011013122A (es) 2012-07-23
US20120329796A1 (en) 2012-12-27
US9908869B2 (en) 2018-03-06
DK2440547T3 (da) 2023-02-20
KR20180100736A (ko) 2018-09-11
KR20120051643A (ko) 2012-05-22
KR20120054585A (ko) 2012-05-30
MX364282B (es) 2019-04-22
JP2020045342A (ja) 2020-03-26
JP5826745B2 (ja) 2015-12-02
EP2440545B1 (en) 2019-04-24
CN103948594B (zh) 2016-10-26
MX340095B (es) 2016-06-27
HRP20230143T1 (hr) 2023-03-31
BRPI1010772B8 (pt) 2021-05-25
CN102596935A (zh) 2012-07-18
MX364280B (es) 2019-04-22
CN104844510A (zh) 2015-08-19
AU2010258294B2 (en) 2015-07-30
BRPI1010768C8 (pt) 2020-04-07
JP6158250B2 (ja) 2017-07-05
TR201910781T4 (tr) 2019-08-21
KR20180101727A (ko) 2018-09-13
US20120283265A1 (en) 2012-11-08
CA2764024C (en) 2017-12-05
CN102574835B (zh) 2014-04-16
WO2010143170A3 (en) 2011-08-11
CA2764027A1 (en) 2010-12-16
BRPI1012892A2 (pt) 2018-03-13
KR101982462B1 (ko) 2019-05-24
BR122019013686B1 (pt) 2020-03-17
JP5905385B2 (ja) 2016-04-20
PT2440545T (pt) 2019-07-19
EP3521283B1 (en) 2024-02-28
MX364989B (es) 2019-05-17

Similar Documents

Publication Publication Date Title
CU24461B1 (es) Compuestos útiles para tratar envejecimiento prematuro y en particular progeria
CU24099B1 (es) Derivados de sulfonamida para el tratamiento del dolor
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
DOP2012000149A (es) Compuestos triciclicos novedosos
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CR20140413A (es) Inhibidores de serina/treonina cinasa
EA200970856A1 (ru) Ингибиторы пути хеджхога
NZ600210A (en) Substituted 4-aminocyclohexane derivatives
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
CL2015000019A1 (es) Composicion farmaceutica que comprende rifaximina cristalina, polimorfa o amorfa, como un hidrato o solvato y/o en una mezcla de la misma y uno o mas aminoacidos; procedimiento de preparacion de la composicion; cristales de rifaximina; su procedimiento de preparacion.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EP2581372A4 (en) CYANOCHINOLINDERIVATE
EA201270261A1 (ru) Соли леналидомида
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
IN2012DN02555A (es)
MY162991A (en) Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
MY162548A (en) New secondary 8-hydroxyquinoline-7-carboxamide derivatives
AR081219A1 (es) Preparacion de clorhidrato de ezatiostat cristalino ansolvatado forma d
GT200500016A (es) Compuestos de quinolina sustituidos
EA201300160A1 (ru) 2,3,5-тризамещенные тиофены и их применение
CU20150028A7 (es) QUINOLIN-2-AMINA Y QUINOXALINA DERIVADOS DE LA FÓRMULA (Ik) y (Ip) Y SALES DERIVADAS